@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAd3bDLVL99tP3b4dWBV6q4Km4M27hajWLWSc4hJ27aTw> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAd3bDLVL99tP3b4dWBV6q4Km4M27hajWLWSc4hJ27aTw#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasPart: <http://purl.obolibrary.org/obo/BFO_0000051> .
@prefix ProteinComplex: <http://amigo.geneontology.org/amigo/term/GO:0043234> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasPart: sub:_2, sub:_3;
    a ProteinComplex: .
  
  sub:_2 geneProductOf: hgnc:7668;
    a Protein: .
  
  sub:_3 geneProductOf: hgnc:3467;
    a Protein: .
  
  sub:_4 hasAgent: sub:_5;
    a go:0042789 .
  
  sub:_5 geneProductOf: hgnc:3467;
    a Protein: .
  
  sub:_6 occursIn: mesh:D001940, mesh:D010053, species:9606;
    rdf:object sub:_4;
    rdf:predicate belv:directlyIncreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "complex(p(HGNC:NCOA1),p(HGNC:ESR1)) => tscript(p(HGNC:ESR1))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_8;
    pav:version "1.4" .
  
  sub:_7 prov:value "in a substantial proportion of patients with primary breast cancer, and in all patients with ER positive metastatic disease, resistance eventually develops to all strategies that are designed to limit ER activation by oestrogen. ER binds as a dimer to small palindromic DNA motifs - known as oestrogen response elements (EREs) - in the promoters of these genes, through the action of two ZINC FINGERS 29. AF1 and AF2 activate transcription independently and/or synergistically. There is evidence that AF1 and AF2 activities are influenced by the promoter and cell type 32. Three related co-activators, collectively known as the p160 co-activators, stimulate ER activity following ligand stimulation, through direct interaction with AF2 (reviewed in REFS 45,46).";
    prov:wasQuotedFrom pubmed:12635173 .
  
  sub:_8 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:12635173;
    prov:wasDerivedFrom beldoc:, sub:_7 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:11.013+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}